ProCE Banner Activity

PACIFIC-2: Final Analysis of Concurrent Durvalumab + CRT Followed by Consolidation Durvalumab for Unresectable Stage III NSCLC

Conference Coverage

In patients with unresectable stage III NSCLC, concurrent durvalumab plus chemoradiotherapy followed by durvalumab consolidation did not significantly improve PFS or OS compared with chemoradiotherapy and placebo in the phase III PACIFIC-2 trial.

Released: April 29, 2024

Expiration: April 28, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc